RESEARCH TRIANGLE PARK, NC--(Marketwire - January 28, 2010) - Business intelligence firm Cutting Edge Information announces the release of its newest study on the global cancer market, "Oncology Market Forecast to 2015: Brand Spending and Development Opportunities." A complimentary summary is available for download at:

When CEI first delved into the cancer market, its original oncology forecasting report ranked in the company's top-seller list for 2009. See here: ( The latest study builds on the analysis, delving into the clinical, commercial, and regulatory trends affecting oncology therapeutics today -- as well as their impact in the decade ahead.

CEI's new report details the historical, current and forecasted performance of 120 drugs treating various forms of cancer and their associated complications. The report's scope encompasses marketed brands and pipeline products in clinical development. Factors examined for each drug include sales projections, market assessments, product longevity, positive or negative clinical trial results and target patient populations. Besides highlighting individual drugs, the report analyzes the strengths, challenges and growth opportunities of each of the top 13 drug makers in oncology.

A key component in the study is real-world, market-focused expenditures from the pre-clinical period through the first year on the market, along with budgeting data from brand directors/managers, marketing team members and executives from 15 different companies.

"Altogether the profiled brands generated $64 billion in 2009, and oncology is poised to be the highest-grossing therapeutic area within the next few years," said Jeremy Spivey, Cutting Edge Information senior analyst. "This report explores competitive forces and business development possibilities, and its spending benchmarks will enable teams to develop their budgets."

The report is organized into brand profiles, drug manufacturer profiles and benchmark data.

Brand Profiles detail a product's historical background, market outlook, and patent and litigation data. Profiles include the following information:

--  Drug's current and projected competitive strength
--  Current/projected sales position within its class
--  Sales projection charts for the next four to seven years
--  Assessment of competition
--  Materiality charts
--  Clinical trial information

Company Profiles show breakdowns for 13 companies that have established cancer franchises or exciting development pipelines. Profiles contain:

--  Oncology ranking
--  Overall industry ranking
--  Strengths analysis
--  Growth areas analysis
--  Competition analysis
--  Key products breakdown

For more information, please visit

Contact Information: MEDIA CONTACT: Stephanie Swanson 919-433-0212